Improving follow-up after an eye screening referral
Official title: Village Integrated Eye Worker II Linkage-to-Care Trial
Run by University of California, San Francisco · NCT06943599 · Data updated 2026-11-12
This trial tries text message or health worker reminders to help people referred after an eye screening get to their hospital appointment within 21 days.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 60 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Status | Recruiting |
| Started | February 1, 2026 |
| Main results expected | June 30, 2028 |
| Study ends | June 30, 2028 |
| Registry record updated | April 29, 2026 |
| Trial ID | NCT06943599 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are VIEW II participants who were referred to the eye hospital at their screening visit and can receive SMS messages if randomized to that arm.
✕Probably not a fit
Patients who are not referred, who lack reliable mobile connectivity, or who already attend appointments promptly may not gain additional benefit from these interventions.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants in the VIEW II screening program who are referred to the eye hospital are randomized into three parallel arms: SMS reminders, health worker reminders, or no additional intervention. The primary outcome is whether the participant presents to the eye hospital for the referral visit within 21 days of screening. The trial focuses on linkage-to-care for age-related macular degeneration, diabetic retinopathy, and glaucoma referrals and measures how each approach affects attendance and retention. Participants living in areas without reliable mobile connectivity are excluded because they cannot reliably receive SMS reminders.
Why it matters
Potential benefit: If successful, the interventions could increase timely attendance at referral visits and enable earlier treatment to help prevent vision loss.
How similar studies have gone: Previous programs using SMS reminders and community health worker outreach have improved clinic attendance in other conditions and settings, though evidence specifically for eye-disease referral outcomes is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Participant of the VIEW II study referred to the eye hospital at their eye screening visit. Exclusion Criteria: * Residence in an area without reliable mobile connectivity
Where it's running
-
University of California, San Francisco
San Francisco, California, United States Recruiting
Study contacts
- Principal investigator: Jeremy Keenan, MD, MPH — University of California, San Francisco
- Study coordinator: Jeremy Keenan, MD, MPH
- Email: jeremy.keenan@ucsf.edu
- Phone: (415) 476-1442
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Hyperspectral imaging to map retinal and optic nerve structures
This study will test whether hyperspectral retinal imaging can detect disease-related features in adults with diabetic retinopathy, glaucoma, age-related macular degeneration, and in healthy volunteers.
-
Vision screening in general practice to catch preventable sight loss in people over 70
This project will test a GP-based vision-screening program for people aged 70 and older with at least one chronic condition to find sight problems early.
-
Community-based eye screening program to prevent blindness
This study is testing whether a community eye screening program in Nepal can help prevent avoidable blindness by catching eye problems early.
-
High Resolution Imaging OCT Study
This study tests whether two investigational OCT devices (R1 and HighRes OCT) produce better image quality than the standard Spectralis in adults with normal eyes or with AMD, diabetic retinopathy, or other retinal diseases.
-
Watching a short video before anti-VEGF eye injections
This trial will test whether watching a brief procedural video before a first anti-VEGF intravitreal injection helps people with retinal diseases feel less anxious and have fewer or smaller subconjunctival hemorrhages.
-
New peptide therapy for retinal diseases
This study is testing a new peptide therapy to see if it can help adults with retinal diseases like age-related macular degeneration and diabetic retinopathy improve their vision and eye health.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.